Since then, several randomised trials have shown that NSCLC patients with activating EGFR gene mutations are responsive to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib [5–12]. Here, EGFR is linked to non-small cell lung carcinoma.